University of Colorado Cancer Center
Playback speed
10 seconds
ES-SCLC Paradigm Change Following IMpower133 and CASPIAN Trials: What Is the Role of Durvalumab in 1L Setting? How Does the Addition of Atezolizumab to CP/ET Affect Patient Outcomes?
By
University of Colorado Cancer Center
FEATURING
Jose Pacheco
By
University of Colorado Cancer Center
FEATURING
Jose Pacheco
632 views
August 17, 2020
Comments 0
Login to view comments.
Click here to Login
Videos